- Home
- DMB vs CKPT Comparison
DMB vs CKPT Comparison
Compare DMB & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMB
- CKPT
- Stock Information
- Founded
- DMB 2013
- CKPT 2014
- Country
- DMB United States
- CKPT United States
- Employees
- DMB N/A
- CKPT N/A
- Industry
- DMB Trusts Except Educational Religious and Charitable
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- DMB Finance
- CKPT Health Care
- Exchange
- DMB Nasdaq
- CKPT Nasdaq
- Market Cap
- DMB 197.7M
- CKPT 214.4M
- IPO Year
- DMB N/A
- CKPT 2017
- Fundamental
- Price
- DMB $10.33
- CKPT $3.61
- Analyst Decision
- DMB
- CKPT Strong Buy
- Analyst Count
- DMB 0
- CKPT 3
- Target Price
- DMB N/A
- CKPT $10.33
- AVG Volume (30 Days)
- DMB 76.6K
- CKPT 2.4M
- Earning Date
- DMB 01-01-0001
- CKPT 11-12-2024
- Dividend Yield
- DMB 4.17%
- CKPT N/A
- EPS Growth
- DMB N/A
- CKPT N/A
- EPS
- DMB N/A
- CKPT N/A
- Revenue
- DMB N/A
- CKPT $47,000.00
- Revenue This Year
- DMB N/A
- CKPT N/A
- Revenue Next Year
- DMB N/A
- CKPT $151,162.55
- P/E Ratio
- DMB N/A
- CKPT N/A
- Revenue Growth
- DMB N/A
- CKPT N/A
- 52 Week Low
- DMB $8.94
- CKPT $1.38
- 52 Week High
- DMB $11.79
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- DMB 21.84
- CKPT 41.64
- Support Level
- DMB $10.89
- CKPT $2.98
- Resistance Level
- DMB $10.99
- CKPT $4.44
- Average True Range (ATR)
- DMB 0.12
- CKPT 0.42
- MACD
- DMB -0.08
- CKPT -0.10
- Stochastic Oscillator
- DMB 1.80
- CKPT 25.66
About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.